Sandoz Co-Amoxiclav Defect Notification EL(26)A/46: MHRA Issues Dosing Error Alert

• Sandoz Limited issued a Class 4 Medicines Defect Notification, EL(26)A/46, regarding errors in the SmPC for Co-amoxiclav powder for oral suspension.
• The defective SmPC's dosing table instructed approximately twice the recommended dose for weight-adjusted administration.
• The physical quality of the Co-amoxiclav powder itself is not impacted by this documentation error.
• The MHRA has removed the incorrect SmPC from its websites, and it will only return after Sandoz secures a market authorization variation for a corrected version.
• There is a potential for overdose and increased risk of adverse effects, prompting advice for patients to seek medical attention if symptoms occur.

The defective SmPC's dosing table instructed an amount of oral suspension that would deliver approximately twice the intended and recommended dose.

Sandoz Limited has issued a Class 4 Medicines Defect Notification, EL(26)A/46, to the Medicines and Healthcare products Regulatory Agency (MHRA) concerning errors identified in the Summary of Product Characteristics (SmPC) for its Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension. The core issue lies within the dosing table, specifically Section 4.2, which provides instructions for weight-adjusted administration of the medication. This table was found to be incorrect, potentially leading to significant dosing inaccuracies.

Investigations revealed that the defective SmPC's dosing table instructed an amount of oral suspension that would deliver approximately twice the intended and recommended dose. While the physical quality of the Co-amoxiclav powder for oral suspension itself remains unaffected by this defect, the documentation error carries substantial implications for patient safety. All batches of the product are currently impacted by this SmPC discrepancy, necessitating immediate action from healthcare providers.

In response to this critical finding, the MHRA has removed the defective SmPC from both its official products website and the electronic medicines compendium (eMC) websites. This measure ensures that healthcare professionals cannot inadvertently access or utilize the erroneous dosing information. The active ingredients of the affected product are amoxicillin trihydrate and potassium clavulanate, identified by SNOMED code 43647311000001107 and GTIN 05015915880116.

The MHRA's Class 4 Medicines Defect Notification serves as a crucial alert to the healthcare system, emphasizing that the Sandoz SmPC for Co-amoxiclav powder oral suspension dosing error must not be used for calculating weight-adjusted administration. Sandoz Limited has provided corrected dosing information, which is detailed in Annex 1 of the original notification, to guide appropriate prescribing and dispensing practices.

The defective SmPC will remain unavailable on the MHRA and eMC platforms until Sandoz secures a granted variation to their market authorization. This regulatory step is essential for the approval and publication of a new, corrected SmPC, ensuring that all published documentation accurately reflects safe and appropriate dosing guidelines. This process underscores the stringent regulatory oversight required for pharmaceutical products in the UK.

Compliance officers and legal counsel within healthcare organizations should note the specific reference, EL(26)A/46, to ensure all relevant personnel are aware of this MHRA medicines defect Sandoz notification. Adherence to these directives is paramount for mitigating potential Co-Amoxiclav overdose risk UK and avoiding regulatory penalties associated with non-compliance.

The primary concern stemming from the Sandoz SmPC dosing table incorrect information is the potential for an overdose, which could significantly increase the likelihood of known dose-related adverse effects. These include a heightened risk of hypersensitivity reactions and other adverse drug reactions associated with Co-amoxiclav. Healthcare providers are explicitly advised not to use the Sandoz SmPC for calculating dosing for weight-adjusted administration of this medicine.

Patients currently taking this medication are advised to continue their prescribed regimen. However, if individuals believe they have taken or administered the higher dose of Co-amoxiclav and are experiencing any side effects such as diarrhoea, nausea, vomiting, or abdominal pain, they should seek immediate medical advice. For any uncertainties or questions regarding their medication, patients and caregivers should consult their pharmacy or other healthcare professionals involved in their treatment.

All suspected adverse reactions to the medication should be reported via the MHRA Yellow Card scheme to contribute to ongoing pharmacovigilance efforts. For medical information enquiries or specific product information related to this issue, Sandoz Limited can be contacted directly via email at mi.uk@sandoz.com or by telephone at 01276 698101. NHS regional teams have been requested to disseminate this critical information to community pharmacists and dispensing general practitioners to ensure widespread awareness and prevent patient harm.

Lawyers should advise clients in healthcare or pharmaceutical distribution on potential product liability exposure due to the incorrect Sandoz SmPC dosing table, and ensure compliance with MHRA defect notifications to mitigate overdose risks and regulatory penalties. Compliance officers must verify that all relevant personnel are aware of the corrected dosing information and that internal protocols reflect this change to avoid patient harm and legal repercussions.

Source: Original reporting via GOV.UK